A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers

Sandra Hocke, Yang Guo, Albert Job, Michael Orth, Andreas Ziesch, Kirsten Lauber, Enrico N. De Toni, Thomas M. Gress, Andreas Herbst, Burkhard Göke,

Oncotarget · 2016 · 41 citations · 46 references

DOIFull text

Open access

Concepts

Abstract

// Sandra Hocke 1 , Yang Guo 1 , Albert Job 2 , Michael Orth 3 , Andreas Ziesch 1 , Kirsten Lauber 3 , Enrico N. De Toni 1 , Thomas M. Gress 2 , Andreas Herbst 1 , Burkhard Göke 1 , Eike Gallmeier 1, 2 1 Department of Medicine II, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany 2 Department of Gastroenterology, Endocrinology and Metabolism, University Hospital of Marburg, Philipps-University of Marburg, 35043 Marburg, Germany 3 Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany Correspondence to: Eike Gallmeier, e-mail: Eike.Gallmeier@med.uni-marburg.de Keywords: ATR, POLD1, synthetic lethality, DNA repair, targeted therapy Received: August 04, 2015     Accepted: January 01, 2016     Published: January 09, 2016 ABSTRACT The phosphoinositide 3-kinase-related kinase ATR represents a central checkpoint regulator and mediator of DNA-repair. Its inhibition selectively eliminates certain subsets of cancer cells in various tumor types, but the underlying genetic determinants remain enigmatic. Here, we applied a synthetic lethal screen directed against 288 DNA-repair genes using the well-defined ATR knock-in model of DLD1 colorectal cancer cells to identify potential DNA-repair defects mediating these effects. We identified a set of DNA-repair proteins, whose knockdown selectively killed ATR -deficient cancer cells. From this set, we further investigated the profound synthetic lethal interaction between ATR and POLD1 . ATR -dependent POLD1 knockdown-induced cell killing was reproducible pharmacologically in POLD1-depleted DLD1 cells and a panel of other colorectal cancer cell lines by using chemical inhibitors of ATR or its major effector kinase CHK1. Mechanistically, POLD1 depletion in ATR -deficient cells caused caspase-dependent apoptosis without preceding cell cycle arrest and increased DNA-damage along with impaired DNA-repair. Our data could have clinical implications regarding tumor genotype-based cancer therapy, as inactivating POLD1 mutations have recently been identified in small subsets of colorectal and endometrial cancers. POLD1 deficiency might thus represent a predictive marker for treatment response towards ATR- or CHK1-inhibitors that are currently tested in clinical trials.

References

46